STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 99 filers reported holding STOKE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.42 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $26,863 | -75.9% | 6,818 | -35.1% | 0.00% | – |
| Q2 2023 | $111,689 | +236.0% | 10,507 | +163.3% | 0.00% | – |
| Q1 2023 | $33,245 | +3501.8% | 3,991 | +3891.0% | 0.00% | – |
| Q4 2022 | $923 | -81.5% | 100 | -70.9% | 0.00% | – |
| Q3 2022 | $5,000 | -37.5% | 344 | -40.2% | 0.00% | – |
| Q2 2022 | $8,000 | -75.8% | 575 | -63.0% | 0.00% | – |
| Q1 2022 | $33,000 | -82.9% | 1,555 | -80.7% | 0.00% | – |
| Q4 2021 | $193,000 | -31.6% | 8,041 | -27.4% | 0.00% | – |
| Q3 2021 | $282,000 | +66.9% | 11,075 | +120.2% | 0.00% | – |
| Q2 2021 | $169,000 | -61.9% | 5,029 | -55.9% | 0.00% | – |
| Q1 2021 | $444,000 | -10.7% | 11,416 | +42.2% | 0.00% | – |
| Q4 2020 | $497,000 | +160.2% | 8,030 | +40.9% | 0.00% | – |
| Q3 2020 | $191,000 | -22.0% | 5,700 | -44.5% | 0.00% | – |
| Q2 2020 | $245,000 | -49.6% | 10,271 | -51.6% | 0.00% | – |
| Q1 2020 | $486,000 | -4.7% | 21,210 | +17.6% | 0.00% | – |
| Q4 2019 | $510,000 | +589.2% | 18,030 | +424.0% | 0.00% | – |
| Q3 2019 | $74,000 | – | 3,441 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 296,822 | $7,551,000 | 1.86% |
| RTW INVESTMENTS, LP | 3,644,248 | $92,710,000 | 1.40% |
| Cormorant Asset Management, LP | 1,278,276 | $32,519,000 | 1.32% |
| Redmile Group, LLC | 2,381,958 | $60,597,000 | 1.06% |
| HighVista Strategies LLC | 47,594 | $1,211,000 | 0.80% |
| Birchview Capital, LP | 15,000 | $382,000 | 0.26% |
| GILDER GAGNON HOWE & CO LLC | 1,123,355 | $28,578,000 | 0.15% |
| Artal Group S.A. | 250,000 | $6,360,000 | 0.14% |
| Tekla Capital Management LLC | 99,263 | $2,525,000 | 0.08% |
| Casdin Capital, LLC | 120,000 | $3,053,000 | 0.08% |